Abstract:Objective To evaluate the clinical results of treatment for osteosarcoma of the extremities with adjuvant chemotherapy regimen Methods Sixty seven patients with ⅡB extremity osteosarcoma were treated with the combination of adjuvant chemotherapy regimen and definitive surgery Forty seven of them were male and twenty four were female The mean age of the patients at the time of diagnosis was 20 years (ranged 10～51 years) Sixty four lesions involved the lower extremity, with 45 involving the distal femur, 14 the upper tibia, 3 the upper fibula and 2 the proximal femur; Three involved the upper end of the humerus The study of subtype of osteosarcoma revealed that 51 were osteoblastic, 6 chondroblastic, 5 fibroblastic and 5 the other subtypes The patients were divided into three groups according to the adjuvant chemotherapy regimen given, the first group consisted of 23 cases, who were treated with the combination of the presurgical cisplatin hyperthermic isolated limb perfusion (CDP-HILP) and postoperative chemotherapy; the second group of 20 cases, who were treated with the combination of the presurgical CBP-HILP and postoperative chemotherapy; and the other 24 cases were treated with postoperative chemotherapy alone Twenty nine of the 67 patients treated surgically had limb salvage procedures; 35 had amputations and 3 had Tikhoff-Limbergs surgery Multiple histologic sections were procured and examined from each of the surgical specimens in the patients who were treated with preoperative HILP to determine the effect of chemotherapy All patients were followed from 3 to 9 years, and the data were statistically analeyed using SPSS 7 0 Results Among 67 cases, 41 (61 19%) had relapse free survival(RFS) in 2 years after surgery, 37 (55 22%) had RFS in 3 years after surgery, and RFS probability at 5 years after surgery was 49 56% Log-rank analysis showed no significant difference in RFS probability among the three groups(P=0 517 1), but there was a significant difference in RFS probability between patients who had limb salvage procedure and those had amputation(P=0 009 7) Age, sex, site and subtype were not significant prognostic variables in this group of patients Correction analysis revealed that the RFS probability were not related with the rate of the tumor necrosis (P=0 058) Conclusion The data revealed that 1) The chemotherapy regimen mainly including platinic drugs was effective treatment for osteosarcoma ,and was more simple and less expensive than any previous reported chemotherapy for steosarcoma, 2) CDP of chemotherapy regimen for osteosarcoma, which had more nephritic and audio toxicity could be replaced by CBP , And 3)Whether the preoperative chemotherapy is suitable for the patients in whom amputation is inevitable (based on age ,size, and involvement of local structure) remains unclear

Response of osteosarcoma to neoadjuvant therapy: evaluated by FDG positron emission tomography

Assessment of Chemotherapy Response Using Fdg-Pet in Pediatric Bone Tumors: A Single Institution Experience

Response of osteogenic sarcoma to neoadjuvant therapy: evaluated by 18F-FDG-PET

18F-FDG PET/CT for the Early Prediction of the Response Rate and Survival of Patients with Recurrent or Metastatic Breast Cancer.

Meta analysis of ~(18)F-deoxyglucose-positron emission tomography value in evaluation of response to therapy for primary bone and soft tissue sarcomas

[Value of Thallium-201 Scintigraphy in Assessment of Neoadjuvant Chemotherapy for Osteosarcoma].

18F-FDG PET Metabolic Parameters for the Prediction of Histological Response to Induction Chemotherapy in Osteosarcoma and Ewing Sarcoma

Clinical evaluation of drug efficiency in primary malignant bone tumors

18 F-FDG PET Metabolic Parameters for the Prediction of Histological Response to Induction Chemotherapy in Osteosarcoma and Ewing Sarcoma : A Systematic Review and Network Meta-analysis

The assessment of the effectiveness of the adjuvant chemotherapy regimen for the treatment of osteosarcoma

18F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis

Comparison of Cell Proliferation, Protein, and Glucose Metabolism in Musculoskeletal Tumors in a PET Study.

Comparative study of 68Ga-DOTATATE and 18F-FDG PET/CT imaging in the detection of bone metastasis in neuroendocrine neoplasm

Comparison Between ~(18)F-Fluorodeoxyglucose Positron Emission Tomography/computed Tomography(pet/ct) and Conventional Imagings in Detection of the Primary Tumor of Patients with Bone Metastasis

18FDG PET/CT in therapeutic assessment and prognostic of non-small cell lung cancer

Usefulness of 18F-FDG PET/CT for Evaluating Response of Breast Cancer to Neoadjuvant Therapy

Overall survival and short-term efficacy analysis of cervical squamous cell carcinoma with skeletal muscle and 18F-FDG PET/CT parameters

A Comparison Between Preoperative PET/CT and CT Images of Long Bone Osteosarcoma of the Lower Extremity

Correction To: an Evaluation of the Response to Neoadjuvant Chemotherapy for Osteosarcoma of Extremities: PERCIST Versus RECIST 1.1 Criteria after Long-Term Follow-Up

The Evaluation of MRI Imaging in Monitoring the Response of Osteosarcoma to Preoperative Neoadjuvant Chemotherapy

Prognostic usefulness of clinical features and pretreatment <SUP>18</SUP>F-FDG PET/CT metabolic parameters in patients with angiosarcoma